Two crystal structures of human neutrophil collagenase, one complexed witha primed- and the other with an unprimed-side inhibitor: Implications for drug design

Citation
E. Gavuzzo et al., Two crystal structures of human neutrophil collagenase, one complexed witha primed- and the other with an unprimed-side inhibitor: Implications for drug design, J MED CHEM, 43(18), 2000, pp. 3377-3385
Citations number
60
Categorie Soggetti
Chemistry & Analysis
Journal title
JOURNAL OF MEDICINAL CHEMISTRY
ISSN journal
00222623 → ACNP
Volume
43
Issue
18
Year of publication
2000
Pages
3377 - 3385
Database
ISI
SICI code
0022-2623(20000907)43:18<3377:TCSOHN>2.0.ZU;2-N
Abstract
Two crystal structures of human neutrophil collagenase (HNC, MMP-8), one co mplexed with a primed- and the other with an unprimed-side inhibitor, were determined using synchrotron radiation at 100 K. Both inhibitors contain no n-hydroxamate zinc-binding functions. The Pro-Leu-L-Trp(P)(OH)(2) occupies the unprimed region of the active site, furnishes new structural informatio n regarding interaction between the catalytic zinc ion and the phosphonate group, and is the only example of occupation of the S-1 subsite of MMP-8 by the bulky tryptophan side chain. The (R)-2-(biphenyl-4-ylsulfonyl)-1,2,3,4 -tetrahydroisochinolin-3-carboxylic acid, a conformationally constrained D- Tic derivative, accommodates its biphenyl substituent into the deep primary specificity S-1' subsite, inducing a widening of the entrance to this pock et; this modification of the protein, mainly consisting in a shift of the s egment centered at Pro217, is observed for the first time in MMP-8 complexe s. Cation-aromatic interactions can stabilize the formation of both complex es, and the beneficial effect of aromatic substituents in proximity of the catalytic zinc ion is discussed. The phosphonate group bound to either a pr imed- or unprimed-side inhibitor maintains the same relative position with respect to the catalytic zinc ion, suggesting that this binding function ca n be exploited for the design of combined inhibitors assembled to interact with both primed and unprimed regions of the active cleft.